Search | Clinical Trials Finder

Conditions: Pain Management, Abortion, Second Trimester Abortion, Dilation and Evacuation
Interventions: Ketorolac, oral ibuprofen, Placebo, Lidocaine HCl 1%, Saline; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Dyslipidemias
Interventions: Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Uterine Cervical Dysplasia
Interventions: Amolimogene, Placebo; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 13 Years to 25 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more

Conditions: Cystic Fibrosis
Interventions: Recombinant Human DNase (Pulmozyme), Placebos; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Month to 30 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Interventions: Efprezimod alfa, Placebo, Methotrexate, Tacrolimus; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more

Conditions: Sjogren's Syndrome, Cough
Interventions: Dornase alfa, Saline; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Systemic Lupus Erythematosus
Interventions: IFNα-Kinoid, Placebo, ISA 51 VG; Biological · Other
Lead sponsor: Neovacs; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more

Conditions: COVID-19
Interventions: RBT-9 (90 mg), 0.9% sodium chloride (normal saline); Drug
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more

Conditions: Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions: Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Influenza Type A, Influenza Type B, Influenza
Interventions: SAB-176, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nervous System Disease, Genetic Syndrome
Interventions: EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo; Drug
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Breast Cancer
Interventions: Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl); Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Sepsis, Septic Shock, Metabolic Disturbance
Interventions: vitamin C, vitamin B1, hydrocortisone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more

Conditions: Sialorrhea
Interventions: Incobotulinum Toxin A, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: AZD3152, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more

Conditions: Femoral Neck Fractures
Interventions: Tranexamic Acid, Placebo (saline); Drug
Lead sponsor: UConn Health; Other
Eligibility: 55 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Major Depressive Disorder
Interventions: ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents; Drug · Other · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Elective Orthopedic Surgery
Interventions: Midazolam, Propofol, Saline; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myocardial Infarct
Interventions: RNS60, Placebo; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Variola Major (Smallpox)
Interventions: Placebo, MVA-BN; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Pulmozyme for Sjogren's Associated Cough

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects